Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
2.910
-0.070 (-2.35%)
At close: Aug 29, 2025, 4:00 PM
3.019
+0.109 (3.75%)
After-hours: Aug 29, 2025, 6:15 PM EDT

Lipocine Statistics

Total Valuation

Lipocine has a market cap or net worth of $15.77 million. The enterprise value is -$1.91 million.

Market Cap15.77M
Enterprise Value -1.91M

Important Dates

The last earnings date was Tuesday, August 5, 2025, before market open.

Earnings Date Aug 5, 2025
Ex-Dividend Date n/a

Share Statistics

Lipocine has 5.42 million shares outstanding. The number of shares has increased by 0.60% in one year.

Current Share Class 5.42M
Shares Outstanding 5.42M
Shares Change (YoY) +0.60%
Shares Change (QoQ) +0.06%
Owned by Insiders (%) 2.91%
Owned by Institutions (%) 9.81%
Float 5.26M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 3.70
Forward PS 22.77
PB Ratio 0.91
P/TBV Ratio 0.92
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 12.71, with a Debt / Equity ratio of 0.01.

Current Ratio 12.71
Quick Ratio 12.46
Debt / Equity 0.01
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -23.51% and return on invested capital (ROIC) is -17.96%.

Return on Equity (ROE) -23.51%
Return on Assets (ROA) -16.76%
Return on Invested Capital (ROIC) -17.96%
Return on Capital Employed (ROCE) -32.57%
Revenue Per Employee $263,007
Profits Per Employee -$281,702
Employee Count16
Asset Turnover 0.20
Inventory Turnover n/a

Taxes

In the past 12 months, Lipocine has paid $200 in taxes.

Income Tax 200
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -21.35% in the last 52 weeks. The beta is 1.24, so Lipocine's price volatility has been higher than the market average.

Beta (5Y) 1.24
52-Week Price Change -21.35%
50-Day Moving Average 3.14
200-Day Moving Average 3.70
Relative Strength Index (RSI) 40.16
Average Volume (20 Days) 20,706

Short Selling Information

The latest short interest is 92,963, so 1.72% of the outstanding shares have been sold short.

Short Interest 92,963
Short Previous Month 98,444
Short % of Shares Out 1.72%
Short % of Float 1.77%
Short Ratio (days to cover) 2.87

Income Statement

In the last 12 months, Lipocine had revenue of $4.21 million and -$4.51 million in losses. Loss per share was -$0.84.

Revenue4.21M
Gross Profit 4.21M
Operating Income -5.58M
Pretax Income -8.49M
Net Income -4.51M
EBITDA -5.52M
EBIT -5.58M
Loss Per Share -$0.84
Full Income Statement

Balance Sheet

The company has $17.94 million in cash and $251,519 in debt, giving a net cash position of $17.68 million or $3.26 per share.

Cash & Cash Equivalents 17.94M
Total Debt 251,519
Net Cash 17.68M
Net Cash Per Share $3.26
Equity (Book Value) 17.13M
Book Value Per Share 3.19
Working Capital 16.97M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$4.99 million and capital expenditures -$90,086, giving a free cash flow of -$5.08 million.

Operating Cash Flow -4.99M
Capital Expenditures -90,086
Free Cash Flow -5.08M
FCF Per Share -$0.94
Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of -132.59% and -107.11%.

Gross Margin 100.00%
Operating Margin -132.59%
Pretax Margin -107.10%
Profit Margin -107.11%
EBITDA Margin -131.26%
EBIT Margin -132.59%
FCF Margin n/a

Dividends & Yields

Lipocine does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -0.60%
Shareholder Yield -0.60%
Earnings Yield -28.58%
FCF Yield -32.19%

Analyst Forecast

The average price target for Lipocine is $9.00, which is 209.28% higher than the current price. The consensus rating is "Strong Buy".

Price Target $9.00
Price Target Difference 209.28%
Analyst Consensus Strong Buy
Analyst Count 2
Revenue Growth Forecast (5Y) 36.22%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

The last stock split was on May 12, 2023. It was a reverse split with a ratio of 1:17.

Last Split Date May 12, 2023
Split Type Reverse
Split Ratio 1:17

Scores

Lipocine has an Altman Z-Score of -5.46 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -5.46
Piotroski F-Score 2